Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $36.00

Denali Therapeutics (NASDAQ:DNLI) had its price target increased by BTIG Research from $32.00 to $36.00 in a report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

DNLI has been the topic of a number of other reports. Stifel Nicolaus set a $37.00 target price on Denali Therapeutics in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Wolfe Research began coverage on shares of Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. UBS Group initiated coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating for the company. Finally, Morgan Stanley reissued an “overweight” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.20.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $20.37 on Monday. The company’s 50 day simple moving average is $19.29 and its two-hundred day simple moving average is $17.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77. The stock has a market capitalization of $3.23 billion, a PE ratio of -6.86 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the business earned ($0.67) EPS. Analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is owned by company insiders.

Institutional Trading of Denali Therapeutics

Several large investors have recently added to or reduced their stakes in DNLI. State of Wyoming increased its position in Denali Therapeutics by 24.7% during the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock valued at $44,000 after purchasing an additional 532 shares during the period. Intrust Bank NA boosted its stake in shares of Denali Therapeutics by 5.6% during the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock valued at $184,000 after purchasing an additional 589 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Denali Therapeutics by 1.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock valued at $860,000 after buying an additional 600 shares during the period. Pier 88 Investment Partners LLC increased its position in shares of Denali Therapeutics by 1.1% during the fourth quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock valued at $1,126,000 after buying an additional 760 shares during the period. Finally, Tudor Investment Corp ET AL raised its stake in Denali Therapeutics by 1.7% in the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after buying an additional 920 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.